Virax Biolabs caps at-the-market share sales at about $2.07 million

Virax Biolabs Group Limited filed a prospectus supplement dated September 4, 2026 that updates the maximum amount of ordinary shares the company can sell under its registration statement, based on rules tied to Form F-3 General Instruction I.B.5.¹

Under the recalculated limit, Virax may offer and sell ordinary shares with an aggregate offering price of up to $2,070,060.20 from time to time through Wainwright, a figure that excludes about $3,658,152 in shares already sold under the earlier prospectus supplements dated January 22, 2024 and September 30, 2024.¹ The company noted that if it becomes eligible to sell additional shares under the same rule later on, it will file another prospectus supplement before doing so.¹

The shares trade on the Nasdaq Capital Market under the ticker "VRAX," and closed at $2.56 per share on September 3, 2026.¹

For purposes of the Form F-3 eligibility calculation, the company's public float held by non-affiliates was valued at $8,421,181, based on 1,324,085 shares held by non-affiliates and a $6.36 per-share price, which was the highest Nasdaq closing price in the 60 days up to and including the filing date, reached on July 9, 2026.¹ Separately, Virax reported selling securities with an aggregate market value of $737,000 under the same rule during the 12 months leading up to and including the filing date.¹

The filing also reiterated that Virax qualifies as an emerging growth company under the 2012 JOBS Act and has adopted reduced public reporting requirements permitted for such companies.¹ However, it has opted out of the extended transition period otherwise available to emerging growth companies for adapting to new or revised accounting standards.¹